Inactive Instrument
Company Checkmate Pharmaceuticals, Inc.
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
Business description: Checkmate Pharmaceuticals, Inc.
Number of employees: 31
Sales by Activity: Checkmate Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) |
|---|
Geographical breakdown of sales: Checkmate Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) |
|---|
Executive Committee: Checkmate Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2018-12-11 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 2022-05-30 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 2019-09-30 |
Chris French
CTO | Chief Tech/Sci/R&D Officer | - | 2016-06-30 |
Nouhad Husseini
PRN | Corporate Officer/Principal | - | 2022-05-30 |
Composition of the Board of Directors: Checkmate Pharmaceuticals, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 2022-05-30 |
Company details: Checkmate Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.10% | -8.54% | +40.05% | +66.99% | 63.29B | |
| -0.20% | +7.45% | +10.96% | +73.39% | 54.89B | |
| -0.03% | +3.94% | +9.37% | +91.64% | 53.28B | |
| +0.61% | +2.69% | +27.75% | +50.97% | 45.81B | |
| -1.08% | +2.19% | +21.92% | +131.38% | 43.46B | |
| -3.39% | -0.83% | +254.27% | +571.04% | 40.23B | |
| -1.67% | +6.70% | +14.42% | +56.67% | 33.45B | |
| +1.19% | -4.98% | +29.01% | -0.76% | 23.7B | |
| -1.09% | +4.96% | +35.50% | +26.68% | 23.76B | |
| Average | -1.09% | +0.46% | +49.25% | +118.67% | 42.43B | |
| Weighted average by Cap. | -1.26% | +0.59% | +47.40% | +122.24% |
